Jeen Liu

809 total citations
10 papers, 572 citations indexed

About

Jeen Liu is a scholar working on Statistics and Probability, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeen Liu has authored 10 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Statistics and Probability, 4 papers in Physiology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeen Liu's work include Statistical Methods in Clinical Trials (4 papers), Asthma and respiratory diseases (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Jeen Liu is often cited by papers focused on Statistical Methods in Clinical Trials (4 papers), Asthma and respiratory diseases (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Jeen Liu collaborates with scholars based in United States, Switzerland and United Kingdom. Jeen Liu's co-authors include Angel FowlerTaylor, Niroo Gupta, William R. Lumry, Jonathan Corren, Bobby Q. Lanier, Stephen T. Holgate, Jordi Castellsagué, Jean Bousquet, Theodore Lee and Howard Fox and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Current Medical Research and Opinion and Annals of Allergy Asthma & Immunology.

In The Last Decade

Jeen Liu

9 papers receiving 539 citations

Peers

Jeen Liu

PHYSI

PRM

IA

SP

IMMUN

Keiichiro Imanaka Japan

Marie-Noëlle Robitaille United States

Andrew Fowler United States

A. Chartier France

A. Clarke Canada

V. Grosso Italy

Harm Tiddens Netherlands

Sue Southworth United Kingdom

John F. Lancaster United States

Keiichiro Imanaka Japan

Jeen Liu

91 ×0.2

PHYSI

124 ×0.4

PRM

71 ×0.3

IA

18 ×0.2

SP

21 ×0.4

IMMUN

Citations per year, relative to Jeen Liu Jeen Liu (= 1×) peers Keiichiro Imanaka

Countries citing papers authored by Jeen Liu

Since Specialization

Citations

This map shows the geographic impact of Jeen Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeen Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeen Liu more than expected).

Fields of papers citing papers by Jeen Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeen Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeen Liu. The network helps show where Jeen Liu may publish in the future.

Co-authorship network of co-authors of Jeen Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Jeen Liu. A scholar is included among the top collaborators of Jeen Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeen Liu. Jeen Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Jiao, Jenny, et al.. (2020). Evaluation of alternative confidence intervals to address non‐inferioritythrough the stratified difference between proportions. Pharmaceutical Statistics. 20(1). 146–162. 3 indexed citations

2.

Lim, Jessica, Li Wang, Nicky Best, et al.. (2019). Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias. Therapeutic Innovation & Regulatory Science. 54(4). 850–860. 13 indexed citations

3.

Brin, Mitchell F., Suresh Durgam, Lynn James, et al.. (2019). OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. International Clinical Psychopharmacology. 35(1). 19–28. 39 indexed citations

4.

Yuan, Jiacheng, et al.. (2019). Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls. Journal of Biopharmaceutical Statistics. 29(3). 558–573. 14 indexed citations

5.

Yuan, Jiacheng, et al.. (2018). Clinical Study Design to Assess Both Short- and Long-term Efficacy in Addition to Group Sequential Test on Safety. Therapeutic Innovation & Regulatory Science. 52(6). 690–695.

6.

Lim, Jessica, Rosalind Walley, Jiacheng Yuan, et al.. (2018). Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities. Therapeutic Innovation & Regulatory Science. 52(5). 546–559. 82 indexed citations

7.

Finn, Albert F., Gary N. Gross, Julius van Bavel, et al.. (2003). Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology. 111(2). 278–284. 140 indexed citations

8.

Lanier, Bobby Q., Jonathan Corren, William R. Lumry, et al.. (2003). Omalizumab is effective in the long-term control of severe allergic asthma. Annals of Allergy Asthma & Immunology. 91(2). 154–159. 149 indexed citations

9.

Holgate, Stephen T., Jean Bousquet, Sally E. Wenzel, et al.. (2001). Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality. Current Medical Research and Opinion. 17(4). 233–240. 38 indexed citations

10.

Holgate, Stephen T., Jean Bousquet, Sally E. Wenzel, et al.. (2001). Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality. Current Medical Research and Opinion. 17(4). 233–240. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact